{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:12:01Z","timestamp":1782817921358,"version":"3.54.5"},"reference-count":63,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: The highly \u03b21-selective beta-blocker Landiolol is known to facilitate efficient and safe rate control in non-compensatory tachycardia or dysrhythmia when administered continuously. However, efficacy and safety data of the also-available bolus formulation in critically ill patients are scarce. Methods: We conducted a retrospective cross-sectional study on a real-life cohort of critical care patients, who had been treated with push-dose Landiolol due to sudden-onset non-compensatory supraventricular tachycardia. Continuous hemodynamic data had been acquired via invasive blood pressure monitoring. Results: Thirty patients and 49 bolus applications were analyzed. Successful heart rate control was accomplished in 20 (41%) cases, rhythm control was achieved in 13 (27%) episodes, and 16 (33%) applications showed no effect. Overall, the heart rate was significantly lower (145 (130\u2013150) vs. 105 (100\u2013125) bpm, p &lt; 0.001) in a 90 min post-application observational period in all subgroups. The median changes in blood pressure after the bolus application did not reach clinical significance. Compared with the ventilation settings before the bolus application, the respiratory settings including the required FiO2 after the bolus application did not differ significantly. No serious adverse events were seen. Conclusions: Push-dose Landiolol was safe and effective in critically ill ICU patients. No clinically relevant impact on blood pressure was noted.<\/jats:p>","DOI":"10.3390\/ph16020134","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T04:28:47Z","timestamp":1673929727000},"page":"134","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care\u2014A Retrospective Cross-Sectional Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0057-8200","authenticated-orcid":false,"given":"Sebastian","family":"Schnaubelt","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3099-415X","authenticated-orcid":false,"given":"Felix","family":"Eibensteiner","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-9886","authenticated-orcid":false,"given":"Julia","family":"Oppenauer","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tihanyi","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Clinic Penzing, Vienna Healthcare Group, 1140 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Neymayer","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Brock","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kornfehl","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-2970","authenticated-orcid":false,"given":"Christoph","family":"Veigl","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9196-1936","authenticated-orcid":false,"given":"Valentin","family":"Al Jalali","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Anders","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Clinic Penzing, Vienna Healthcare Group, 1140 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Steinlechner","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia, Intensive Cate Medicine and Pain Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Domanovits","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sulzgruber","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1067\/mcp.2000.108733","article-title":"Pharmacokinetics of Landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias","volume":"68","author":"Atarashi","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejps.2016.06.022","article-title":"Pharmacokinetics and pharmacodynamics of two different Landiolol formulations in a healthy Caucasian group","volume":"92","author":"Krumpl","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/FJC.0000000000000554","article-title":"Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites","volume":"71","author":"Krumpl","year":"2018","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1248\/cpb.40.1462","article-title":"Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101","volume":"40","author":"Iguchi","year":"1992","journal-title":"Chem. Pharm. Bull."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40265-013-0077-4","article-title":"Landiolol: A review of its use in intraoperative and postoperative tachyarrhythmias","volume":"73","author":"Plosker","year":"2013","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF02480087","article-title":"Effect of ONO-1101, a novel short-acting \u03b2-blocker on hemodynamic responses to isoflurane inhalation and tracheal intubation","volume":"12","author":"Hasuo","year":"1998","journal-title":"J. Anesth."},{"key":"ref_7","unstructured":"(2022, February 21). Summary of Product Characteristics of Rapibloc. Available online: https:\/\/mri.cts-mrp.eu\/Human\/Downloads\/NL_H_3368_002_FinalSPC.pdf."},{"key":"ref_8","unstructured":"(2022, February 21). AOP Orphan Pharmaceuticals AG Announces European \u201cApprovable\u201d Opinion of Its Ultra-Short Acting Beta Blocker Rapibloc\u00ae (Landiolol). Available online: https:\/\/www.aop-health.com\/global_en\/our-company\/newsroom-archive\/aop-orphan-pharmaceuticals-ag-announces-european-approvable-opinion-of-its-ultra-short-acting-beta-blocker-rapibloc-r-Landiolol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.116.232884","article-title":"Comparison of the \u03b2-Adrenergic Receptor Antagonists Landiolol and Esmolol: Receptor Selectivity, Partial Agonism, and Pharmacochaperoning Actions","volume":"359","author":"Sucic","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/BF03016588","article-title":"In rabbits, Landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol","volume":"48","author":"Sasao","year":"2001","journal-title":"Can. J. Anaesth."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"Ii21","DOI":"10.1161\/01.HYP.11.3_Pt_2.II21","article-title":"Beta-adrenergic receptor blockers. Adverse effects and drug interactions","volume":"11","author":"Frishman","year":"1988","journal-title":"Hypertension"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.cjca.2013.12.001","article-title":"Contemporary Use of \u03b2-Blockers: Clinical Relevance of Subclassification","volume":"30","author":"Poirier","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"ref_13","first-page":"A433","article-title":"A comparison of Landiolol and esmolol for attenuation of cardiovascular response and plasma renin activity against tracheal intubation with laryngoscopy","volume":"103","author":"Kakuta","year":"2005","journal-title":"Anesthesiology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Krumpl, G., Ul\u010d, I., Trebs, M., Kadlecov\u00e1, P., and Hodisch, J. (2020). Pharmacodynamic and pharmacokinetic behavior of Landiolol during dobutamine challenge in healthy adults. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00462-x"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1254\/jphs.11202FP","article-title":"Direct effects of esmolol and Landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts","volume":"118","author":"Shibata","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"ref_16","first-page":"407","article-title":"The role of the ultra short-acting \u03b21-adrenoreceptor antagonist Landiolol in the treatment of atrial fibrillation: Pharmacology, clinical application and current evidence in anaesthesiology, intensive care and emergency medicine","volume":"59","author":"Gibb","year":"2018","journal-title":"An\u00e4sthesiologie Intensivmed."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00228-016-2176-0","article-title":"Bolus application of Landiolol and esmolol: Comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group","volume":"73","author":"Krumpl","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1253\/circj.CJ-08-0734","article-title":"Beta-arrestin-mediated signaling in the heart","volume":"72","author":"Patel","year":"2008","journal-title":"Circ. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molmed.2010.11.004","article-title":"Therapeutic potential of \u03b2-arrestin- and G protein-biased agonists","volume":"17","author":"Whalen","year":"2011","journal-title":"Trends Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1161\/01.CIR.0000127126.73759.23","article-title":"MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo","volume":"109","author":"Lips","year":"2004","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11010-008-9929-8","article-title":"Prevalent role of Akt and ERK activation in cardioprotective effect of Ca2+ channel- and beta-adrenergic receptor blockers","volume":"321","author":"Kovacs","year":"2009","journal-title":"Mol. Cell. Biochem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1093\/eurheartj\/sux037","article-title":"Landiolol: Pharmacology and its use for rate control in atrial fibrillation in an emergency setting","volume":"20","author":"Domanovits","year":"2018","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/VHRM.S210561","article-title":"Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature","volume":"16","author":"Matsuishi","year":"2020","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(20)30037-0","article-title":"Efficacy and safety of Landiolol, an ultra-short-acting \u03b21-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): A multicentre, open-label, randomised controlled trial","volume":"8","author":"Kakihana","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jclinane.2014.01.017","article-title":"Continuous administration of Landiolol reduced QT dispersion in postoperative patients","volume":"26","author":"Suzuki","year":"2014","journal-title":"J. Clin. Anesth."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0008-6363(01)00509-0","article-title":"Rapid component IKr of the guinea-pig cardiac delayed rectifier K+ current is inhibited by \u03b21-adrenoreceptor activation, via cAMP\/protein kinase A-dependent pathways","volume":"53","author":"Karle","year":"2002","journal-title":"Cardiovasc. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/YCT.0b013e3181a95d8c","article-title":"Prolongation of QT Interval Induced by Electroconvulsive Therapy is Attenuated by Landiolol","volume":"26","author":"Matsura","year":"2010","journal-title":"J. ECT"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"A15","DOI":"10.1093\/eurheartj\/sux039","article-title":"Landiolol for managing atrial fibrillation in intensive care","volume":"20","author":"Rehberg","year":"2018","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00540-007-0573-3","article-title":"Clinical role and efficacy of Landiolol in the intensive care unit","volume":"22","author":"Yoshida","year":"2008","journal-title":"J. Anesth."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5492\/wjccm.v4.i3.251","article-title":"Landiolol, an ultra-short-acting \u03b21-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis","volume":"4","author":"Okajima","year":"2015","journal-title":"World J. Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jjcc.2019.05.012","article-title":"A prospective observational survey on Landiolol in atrial fibrillation\/atrial flutter patients with chronic heart failure\u2014AF-CHF Landiolol survey","volume":"74","author":"Yamashita","year":"2019","journal-title":"J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1253\/circj.CJ-12-1618","article-title":"Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: Comparison of the ultra-short-acting \u03b21-selective blocker Landiolol with digoxin (J-Land Study)","volume":"77","author":"Nagai","year":"2013","journal-title":"Circ. J."},{"key":"ref_34","first-page":"10265","article-title":"Efficacy and safety of Landiolol for prevention of atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12325-014-0111-2","article-title":"Impacts of Patient Characteristics on the Effectiveness of Landiolol in AF\/AFL Patients Complicated with LV Dysfunction: Subgroup Analysis of the J-Land Study","volume":"31","author":"Kinugawa","year":"2014","journal-title":"Adv. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-018-0883-9","article-title":"Landiolol: A Review in Tachyarrhythmias","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1253\/circrep.CR-20-0017","article-title":"Efficacy and Safety of Landiolol in Patients with Ventricular Tachyarrhythmias with or without Renal Impairment\u2014Subanalysis of the J-Land II Study","volume":"2","author":"Shiga","year":"2020","journal-title":"Circ. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00126839-200506060-00006","article-title":"Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of Landiolol hydrochloride, an ultra-short-acting beta1-blocker","volume":"6","author":"Takahata","year":"2005","journal-title":"Drugs R D"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100571","DOI":"10.1016\/j.eclinm.2020.100571","article-title":"Impact of patient characteristics on the efficacy and safety of Landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J-Land 3S randomised controlled study","volume":"28","author":"Matsuda","year":"2020","journal-title":"eClinicalMedicine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinane.2017.07.009","article-title":"Prevention of atrial fibrillation after cardiac surgery using low-dose Landiolol: A systematic review and meta-analysis","volume":"42","author":"Tamura","year":"2017","journal-title":"J. Clin. Anesth."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5761\/atcs.ra.21-00126","article-title":"Beta-Blocker Landiolol Hydrochloride in Preventing Atrial Fibrillation Following Cardiothoracic Surgery: A Systematic Review and Meta-Analysis","volume":"28","author":"Hao","year":"2022","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1253\/circj.CJ-18-1361","article-title":"Efficacy and Safety of the Ultra-Short-Acting \u03b21-Selective Blocker Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhymias\u2014Outcomes of J-Land II Study","volume":"83","author":"Ikeda","year":"2019","journal-title":"Circ. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ehf2.13763","article-title":"Effect of Landiolol in patients with tachyarrhythmias and acute decompensated heart failure (ADHF): A case series","volume":"9","author":"Ditali","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/SHK.0b013e3181863689","article-title":"Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model","volume":"31","author":"Hagiwara","year":"2009","journal-title":"Shock"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.chest.2021.01.009","article-title":"Effect of Ultrashort-Acting \u03b2-Blockers on Mortality in Patients With Sepsis With Persistent Tachycardia Despite Initial Resuscitation: A Systematic Review and Meta-analysis of Randomized Controlled Trials","volume":"159","author":"Hasegawa","year":"2021","journal-title":"Chest"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40560-017-0215-2","article-title":"Sepsis-induced cardiac dysfunction and \u03b2-adrenergic blockade therapy for sepsis","volume":"5","author":"Suzuki","year":"2017","journal-title":"J. Intensive Care"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.jvca.2005.11.009","article-title":"Bolus administration of Landiolol, a short-acting, selective beta1-blocker, to treat tachycardia during anesthesia: A dose-dependent study","volume":"20","author":"Harasawa","year":"2006","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/BF03022072","article-title":"Effectiveness of bolus Landiolol on paroxysmal atrial tachycardia","volume":"52","author":"Kinoshita","year":"2005","journal-title":"Can. J. Anaesth."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1253\/circj.CJ-12-0663","article-title":"Safety and efficacy of a bolus injection of Landiolol hydrochloride as a premedication for multidetector-row computed tomography coronary angiography","volume":"77","author":"Osawa","year":"2013","journal-title":"Circ. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1253\/circj.CJ-19-0661","article-title":"Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation\/Atrial Flutter in Caucasian Patients","volume":"84","author":"Stix","year":"2019","journal-title":"Circ. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00134-017-4832-y","article-title":"Prevention of acute kidney injury and protection of renal function in the intensive care unit: Update 2017: Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine","volume":"43","author":"Joannidis","year":"2017","journal-title":"Intensive Care Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Salahuddin, N., Sammani, M., Hamdan, A., Joseph, M., Al-Nemary, Y., Alquaiz, R., Dahli, R., and Maghrabi, K. (2017). Fluid overload is an independent risk factor for acute kidney injury in critically Ill patients: Results of a cohort study. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0460-6"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/joim.12274","article-title":"Association between fluid balance and survival in critically ill patients","volume":"277","author":"Lee","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"727103","DOI":"10.3389\/fmed.2022.727103","article-title":"A Positive Fluid Balance in the First Week Was Associated With Increased Long-Term Mortality in Critically Ill Patients: A Retrospective Cohort Study","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S12012","DOI":"10.1186\/2110-5820-2-S1-S1","article-title":"Fluid management in critically ill patients: The role of extravascular lung water, abdominal hypertension, capillary leak, and fluid balance","volume":"2","author":"Cordemans","year":"2012","journal-title":"Ann. Intensive Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1164\/rccm.202106-1350OC","article-title":"Association of ICU Admission and Outcomes in Sepsis and Acute Respiratory Failure","volume":"205","author":"Anesi","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.21037\/jtd.2019.04.84","article-title":"Prognosis of patients with acute respiratory failure and prolonged intensive care unit stay","volume":"11","author":"Lai","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13054-015-0803-2","article-title":"\u03b2-blockers in critically ill patients: From physiology to clinical evidence","volume":"19","author":"Coppola","year":"2015","journal-title":"Crit. Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2049-6958-9-8","article-title":"The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit","volume":"9","author":"Kargin","year":"2014","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0954-6111(03)00168-9","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease: A meta-analysis","volume":"97","author":"Salpeter","year":"2003","journal-title":"Respir. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s00134-011-2236-y","article-title":"Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock","volume":"37","author":"Aboab","year":"2011","journal-title":"Intensive Care Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1053\/j.jvca.2019.11.003","article-title":"Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System","volume":"34","author":"Walter","year":"2020","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"41","author":"Brugada","year":"2019","journal-title":"Eur. Heart J."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/2\/134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:08:06Z","timestamp":1760119686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/2\/134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ph16020134"],"URL":"https:\/\/doi.org\/10.3390\/ph16020134","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,17]]}}}